Cingulate begins the last study it needs to submit its leading drug candidate, a precision-timed release ADHD medication, for Food and Drug Administration approval.

Retail chatter around Cingulate spiked Tuesday after Phase 3 data confirmed that its lead candidate, CTx-1301, significantly improved ADHD symptoms in pediatric patients within five weeks of ...

Cingulate Inc. (NASDAQ:CING) shares are surging, trading over 159% higher today. Here’s what’s driving the movement. Why It’s Moving: Cingulate’s stock is soaring following the ...

Targeting the cingulate gyrus, specifically the SCC, was one of the first evaluations of DBS in neuropsychiatric disease.

Cingulate Inc. (NASDAQ: CING) shares are on an upward trajectory Friday. It follows the announcement that Cingulate has been granted European Patent No. 3261625 for its flagship asset, CTx-1301 ...

Pharmaceutical company Cingulate appears to have bolstered its stockholders' equity enough to resolve an oustanding delisting warning from the Nasdaq.

Total gross proceeds to the Company from the offering, before deducting the placement agent’s fees and other offering expenses, are expected to be $7.5 million. The Company intends to use the ...

The limbic system is a group of structures in the brain that help with memory, learning, and emotional regulation. Learn more here.

Cingulate Inc. CING shares are surging, trading over 159% higher today. Here’s what’s driving the movement. Why It’s Moving: Cingulate’s stock is soaring following the announcement that ...